Afformay Dock t No. L A 35 012

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Henning, et al.

Group No.: 2121

Sesia 70.: 10/023,501

Examiner:

Filed: 12/17/2001

For: "Method for Increasing Clinical Specificity When Detecting Tumors and Their Precursor Stages by

Simultaneously Measuring at Least Two Different Molecular Markers"

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date:

AUG 0 1 2002

Mujellen Chadebing
Signature of Person Certifying

RECEIVED

AUG D 8 2002

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Technology Center 2100

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

,Reg. No. 48,972

Telephone: (203) 812-6450

Date: AUG 0 1 2002

Susan M. Pellegrino
Attorney for Applicant(s)
Bayer Corporation

400 Morgan Lane

- 1 -

West Haven, CT 06516

RECEIVED

SEP 1 7 2002

g:\patents\forms\idstrans197b.doc

TE THE CLOGY CENTER R3700



SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

For O-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office Serial No. 10/023,501

Group Art Unit 2121

Atty. Docket No. Filing Date 12/17/2001 Le A 35 012

Applicant(s) Henning, et al.

		U.S. PATENT DOCUMENTS								rechnology Center				
*	DOCUMENT NO.								DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	U3	6	0	0	5	2	5	6	12/21/99	McGlynn, et al.	250	559.4	02/12/98	
	U4	5	5	4	4	6	5	0	08/13/96	Boon, et al.	128	632	02/14/94	

				FO	REIG	N PA	TENT DOCU	JMENTS			r.acs	
DOCUMENT NO.				DATE	COUNTRY	PRIMARY	SUB-	TRANSLATION				
						DD/MM/YY	Y	CLASS	CLASS	YES	NO	
		<u> </u>	İ		Ĺ							

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)
R1	Williams, G., Romanowski, P., Morris, L., Madine, M., Mills, A., Stoeber, K., Marr, J., Laskey, R., Coleman, N., "Improved Cervical Smear Assessment Using Antibiotics Against Proteins That Regulate DNA Replication", Proc. Natl. Acad. Sci. USA, 95: 14932-14937 (Dec., 1998)
R2	Cuzick, J., "Human Papillomavirus Testing For Primary Cervical Cancer Screening", JAMA, 283: 108-109 (Jan., 2000)
R3	Tervahauta, A., Syrjanen, S., Mantyjarvi, R., Syrjanen, K., "Detection of p53 Protein and Ki-67 Proliferation Antigen in Human Papillomavirus (HPV)-Positive and HPV-Negative Cervical Lesions by Immunohistochemical Double-staining", Cytopathology, 5: 282-293 (1994)
R4	Boon, M., Beck, S., Kok, L., "Semiautomatic PAPNET Analysis of Proliferating (MiB-1-Positive) Cells in Cervical Cytology and Histology", Diag. Cytopathology, 13: 423-428 (1995)
R5	Sawaya, G., Washington, A., "Cervical Cancer Screening: Which Techniques Should Be Used and Why?", Clin. Obstetrics and Gynecology, 42: 922-938 (1999)
R6	Sano, T., Oyama, T., Kashiwabara, K., Fukuda, T., Nakajima, T., "Immunohistochemical Overexpression of p16 Protein Associated with Intact Retinoblastoma Protein Expression in Cervical Cancer and Cervical Intraepithelial Neoplasia", Path. Int., 48: 580-585 (1998)
R7	Gomez, F., Roldan, M., Corcuera, M., Picazo, A., Munoz, E., Alonso, M., "Simultaneous Detection of Antigens and Specific DNA Sequences of Human Papillomavirus in Uterine Cervical Biopsy Specimens. Description of a Double-Labelling Technique", Eur. J. Histochem., 41: 255-259 (1997)
R8	Stoler, M., "Advances in Cervical Screening Technology", Mod. Pathol., 13: 275-284 (2000)
R9	Leek, R., Kaklamanis, L., Pezzella, F., Gatter, K., Harris, A., "bcl-2 in Normal Human Breast and Carcinoma, Association With Oestrogen Receptor-Positive, Epidermal Growth Factor Receptor-Negative Tumours and In

EX	A P	. 41	NI:	CD
EA	Λi	VI I	11	c_{κ}

RECEIVED

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in Son formance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant 700

TECHNOLOGY CENTER 43700

	·	AUG 0 5 2002 &					
•		Situ Cancer", Br. J. Cancer, <u>69:</u> 135-139 (1994)					
	R10	Oshika, Y., Nakamura, M., Tokunaga, T., Fukushima, Y., Aberra, Y., Yamazaki, H., Tamaoki, N., Ueyama, Y., "Multidrug Resistance-Associated Protein and Mutant p53 Protein Expression in Non-Small Cell Lung Cancer", Mod. Pathol., 11: 1059-1063 (1998)					
	R11	Kraeft, S., Sutherland, R., Gravelin, L., Hu, G., Ferland, L., Richardson, P., Elias, A., Chen, L., "Detection and Analysis of Cancer Cells in Blood and Bone Marrow Using a Rare Event Imaging System", Clin. Cancer Research, 6: 434-442 (Feb., 2000)					
	R12	Reiner, A., Neumeister, B., Spona, J., Reiner, G., Schemper, M., Jakesz, R., "Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer", Cancer Research, <u>50</u> : 7057-7061 (Nov., 1990)					
	R13	Mokbel, K., Parris, C., Ghilchik, M., Williams, G., Newbold, R., "The Association Between Telomerase, Histopathological Parameters, and KI-67 Expression in Breast Cancer", Am. J. Surgery, <u>178</u> : 69-72 (1999)					

RECEIVED
AUG 0 8 2002
Technology Center 2100



EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.